AMGEN INC (AMGN)
Biological Products, (No Diagnostic Substances) · Biological Products, (No Diagnostic Substances) · NASDAQ
$442.36
+4.02%
Investingg Score
57.3 / 100
Hold
Business overview
- Gross margin stands at 67.2% and operating margin is 24.7%.
- FCF margin is reported at 22%.
These margins demonstrate that the company converts a healthy portion of its revenue into operating income and free cash flow.
Financial health
- Balance Sheet pillar score is recorded at 15 out of 100.
- Free cash flow yield sits at 3.4%.
While the company generates stable cash flows, the low balance sheet score indicates underlying financial structure risks or debt levels that require careful monitoring.
- Gross Margin
- 67.2%
- Operating Margin
- 24.7%
- Current Ratio
- 1.1x
- Debt / Equity
- 5.78
- Free Cash Flow (TTM)
- $8.1B
- Interest Coverage
- 3x
Valuation
- Trailing P/E ratio is 26.96 while the forward P/E ratio drops to 16.86.
- Price-to-sales ratio is 6.37 and EV-to-EBITDA is 22.78.
Together, these multiples suggest that shares are valued fairly relative to near-term expected earnings growth despite elevated trailing multiples.
- P/E (TTM)
- 27.0x
- Forward P/E
- 16.9x
- Price / Sales
- 6.4x
- EV / EBITDA
- 22.8x
- FCF Yield
- 3.4%
Key risks
- Overbought technical conditions indicated by a high RSI of 80.65.
- A weak balance sheet pillar score of 15 representing potential financial leverage risks.
- Uncertainty regarding whether the rapid 88.2% EPS growth rate can be sustained long-term.
Market cap $238.3B · data as of 2026-08-19
Related stocks
Get the full interactive report
Technicals, earnings history, news, bull/base/bear scenarios, Ask the Stock, and more — free to start.
Analyze AMGN with Investingg AINot investment advice. Investingg AI summarizes public data and AI-generated analysis for informational purposes only.